Maxwell, Jessica E.
Naraev, Boris
Halperin, Daniel M.
Choti, Michael A.
Halfdanarson, Thorvardur R.
Funding for this research was provided by:
TerSera Therapeutics, LLC (No grant/award number)
Lexicon Pharmaceuticals, Inc. (No grant/award number)
Article History
Received: 3 February 2021
Accepted: 16 January 2022
First Online: 14 February 2022
Disclosure
: Jessica E. Maxwell has served as a consultant for Ipsen Biopharmaceuticals. Boris Naraev has served as a consultant for Advanced Accelerator Applications, a Novartis Company; Ipsen Biopharmaceuticals; Lexicon Pharmaceuticals, Inc.; Novocure; and Sun Pharma. Daniel M. Halperin has served as a consultant for Advanced Accelerator Applications, a Novartis Company; Curium; Ipsen; Isotopen Technologien München AG; and Lexicon Pharmaceuticals, Inc.; and has received research support from Advanced Accelerator Applications, a Novartis Company; Incyte; Roche/Genentech; Tarveda Therapeutics; TerSera Therapeutics, LLC; and ThermoFisher Scientific. Michael A. Choti reports nothing to disclose. Thorvardur R. Halfdanarson has served as a consultant for Advanced Accelerator Applications, a Novartis Company; Curium; Isotopen Technologien München AG; Ipsen Biopharmaceuticals; Lexicon Pharmaceuticals, Inc; and Terumo; and has received research support from Advanced Accelerator Applications, a Novartis Company; Ipsen Biopharmaceuticals; and ThermoFisher Scientific.